Learn languages naturally with fresh, real content!

Popular Topics
Explore By Region
A gene therapy slowed Huntington’s disease progression by 75% over 3 years in a clinical trial, marking the first disease-modifying treatment for the inherited disorder.
A gene therapy called AMT-130 has slowed Huntington’s disease progression for the first time in a clinical trial, showing a 75% reduction in decline over 36 months for patients receiving a high dose.
Developed by uniQure and tested by University College London, the one-time brain surgery treatment improved or stabilized motor, cognitive, and functional abilities, with lower levels of a brain injury marker.
Researchers called the results transformative, noting some patients remained stable or returned to work.
The therapy, delivered via a single dose, is expected to offer long-lasting benefits and represents the first evidence of a disease-modifying treatment for this inherited neurodegenerative disorder.
Una terapia génica desaceleró la progresión de la enfermedad de Huntington en un 75% durante 3 años en un ensayo clínico, lo que marca el primer tratamiento modificador de la enfermedad para el trastorno hereditario.